查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1990048

CD40配体市场：依产品类型、剂型、适应症及最终用户划分－2026-2032年全球市场预测

CD40 Ligand Market by Product Type, Form, Indication, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

CD40 配体市场预计到 2025 年价值 7.7685 亿美元，到 2026 年成长到 8.1604 亿美元，到 2032 年达到 11.3948 亿美元，年复合成长率为 5.62%。

主要市场统计数据
基准年 2025 7.7685亿美元
预计年份：2026年 8.1604亿美元
预测年份 2032 1,139,480,000 美元
复合年增长率 (%) 5.62%

这是一本权威的 CD40 配体生物学入门书籍，阐述了它们在治疗领域的转化意义，以及策略和开发的基本考虑因素。

CD40配体（CD40L）正逐渐成为一个至关重要的免疫调节靶点，在自体免疫、肿瘤、感染疾病免疫，又能在失调时导致病理性慢性发炎——因此备受转化医学研究的关注。这种复杂性既带来了治疗机会，也带来了安全性挑战，影响着标靶选择、治疗方法製定和临床开发策略。

科学突破、治疗方法创新和发展策略如何从根本上重塑 CD40 配体治疗开发和伙伴关係模式。

随着科学知识的累积、平台技术的成熟以及监管先例的完善，CD40配体领域正经历着一场变革，这些因素共同重塑了研发重点。首先，对CD40L与抗原呈现细胞和B细胞相互作用机制的深入理解，改进了标靶结合策略。研发机构正日益优化互补位设计和Fc工程改造，以期在发挥有​​益的免疫调节作用的同时，降低血栓形成和发炎风险。同时，从具有修饰效应功能的重组单株抗体到胜肽拮抗剂和重组生技药品等新一代治疗方法的涌现，正在拓展科学家和临床医生可用的工具箱。

评估 2025 年美国关税趋势的变化将如何微妙地改变 CD40 配体相关计划的供应链、製造决策和临床开发计划。

到2025年，美国关税政策和更广泛的贸易格局的发展将对CD40配体生态系统产生微妙的影响，波及供应链、试剂成本和跨境合作。关税导致进口原材料、一次性系统和某些生物製剂原材料成本上涨，可能会对临床和商业规模的生产製造造成压力。这些成本趋势往往会对预算有限、与供应商议价能力较弱的中小型生技公司和大学衍生企业造成不成比例的影响。

针对每种适应症，提供可操作的细分见解，包括临床需求、治疗方法影响、最终用户能力和製剂考虑因素，从而实现策略优先排序。

严谨的细分观点清楚地揭示了适应症、产品类型、终端用户和製剂选择等领域中科学机会与商业性潜力的交汇点。针对特定适应症的研究涵盖自体免疫疾病（包括狼疮、多发性硬化症和类风湿性关节炎）、类风湿性关节炎、感染疾病（分为骨髓恶性肿瘤（白血病和淋巴瘤）和固态肿瘤（黑色素瘤和非小细胞肺癌））以及移植排斥反应。每类适应症都有其独特的标靶检验要求、安全性耐受范围和监管预期，这些都会影响试验设计以及试验实施和终止的决策标准。

影响美洲、欧洲、中东和非洲以及亚太地区的区域趋势和战略意义，这些趋势和战略意义影响发展速度、製造和准入战略。

区域趋势在塑造CD40配体计画的临床开发路径、监管策略和商业化方法方面发挥着至关重要的作用。在美洲，先进的临床试验基础设施、成熟的生物製造能力和活跃的投资群体正在加速概念验证（PoC）的开发，并促成早期过渡到关键性试验。该地区的监管对话往往强调可靠的安全性资料集和明确的风险效益论证，这些论证都体现在全球开发计划和标籤策略的发展中。

成熟的製药公司、创新生物技术公司、学术衍生公司和服务合作伙伴之间的竞争与合作动态，塑造了 CD40 配体计画的发展路径。

CD40配体计画的竞争格局呈现出多元化的特点，既有成熟的製药公司，也有创新生物技术公司、学术衍生企业，以及支持转化研究的专业合约研究与生产机构。成熟的机构提供平台规模的生产技术和监管经验，这对后期开发至关重要；而小规模的生物技术公司和学术团队往往是早期创新、新作用机制洞察以及敏捷的临床概念验证试验的来源。

为优先考虑专案、设计伙伴关係、建立供应链韧性以及与监管机构和支付方合作以加速 CD40 配体的成功，提出了切实可行的多方面建议。

产业领导者应采取多管齐下的策略，兼顾科学严谨性和营运韧性，以最大限度地提高CD40配体研发的临床和商业性成功潜力。首先，应优先考虑降低标靶和安全性风险，透过严谨的临床前模型和早期生物标记项目，直接指导患者筛选和终点设计。投资转化医学能力将提高讯号检测的准确性，并增加在早期临床试验中获得明确结果的可能性。

采用透明、多方面的研究途径，结合专家访谈、文献综述和交叉引用信息，确保对 CD40 配体获得可靠的见解和可重复的结论。

本分析的调查方法系统地整合了同行评审文献、监管指南、临床试验註册数据和检验的原始资料，以得出平衡且基于证据的结论。原始资料包括对转化科学家、临床研究人员、生产专家和商业领袖的深入访谈，他们提供了关于治疗方法选择、试验设计、生产限制和区域实施挑战的见解。这些定性研究结果与科学论文、会议报告和公开的监管文件等二级资讯来源进行了交叉比对，以支持主题性发现并识别新出现的信号。

一项权威的、综合性的分析，重点阐述了将 CD40 配体的发现转化为可操作的治疗性介入时，科学预期与实际挑战之间的平衡。

CD40配体研发的整体前景谨慎乐观，但受到技术和营运复杂性的限制。科学进步已明确了其治疗范围，并揭示了在多种适应症中利用或抑制免疫活性的机会。同时，特定疗法的生产需求、安全性考量以及不断变化的市场趋势要求制定务实且资源充足的研发策略。创新与执行之间的平衡将决定哪些项目能够从概念验证（PoC）阶段最终转化为永续的临床效用。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：CD40配体市场：依产品类型划分

  • 基因治疗载体
  • 单株抗体
  • 胜肽
  • 重组蛋白

第九章：CD40配体市场：依形式

  • 液体
  • 冻干粉

第十章：CD40配体市场：依适应症划分

  • 自体免疫疾病
    • 狼疮
    • 多发性硬化症
    • 类风湿性关节炎
  • 感染疾病
  • 肿瘤学
    • 骨髓恶性肿瘤
      • 白血病
      • 淋巴瘤
    • 固体癌
      • 恶性黑色素瘤
      • 非小细胞肺癌
  • 移植排斥

第十一章：CD40配体市场：依最终用户划分

  • 生技公司
  • 合约研究机构
  • 製药公司
  • 研究机构
    • 学术机构
    • 临床实验室

第十二章：CD40配体市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：CD40配体市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：CD40配体市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国CD40配体市场

第十六章：中国CD40配体市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-5D693B46BCF8

The CD40 Ligand Market was valued at USD 776.85 million in 2025 and is projected to grow to USD 816.04 million in 2026, with a CAGR of 5.62%, reaching USD 1,139.48 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 776.85 million
Estimated Year [2026] USD 816.04 million
Forecast Year [2032] USD 1,139.48 million
CAGR (%) 5.62%

Authoritative introduction to CD40 ligand biology, translational significance across therapeutic areas, and foundational considerations for strategy and development

CD40 ligand (CD40L) has emerged as a pivotal immunomodulatory target with broad implications across autoimmunity, oncology, infectious disease, and transplant medicine. At the molecular level, CD40L functions as a critical co-stimulatory signal, shaping B cell maturation, dendritic cell activation, and effector T cell responses. Translational interest has been driven by the pathway's dual role in promoting effective anti-tumor immunity while also contributing to pathogenic chronic inflammation when dysregulated. This complexity creates both therapeutic opportunity and safety challenges that influence target selection, modality choice, and clinical development strategy.

Contemporary research programs are approaching CD40L with a spectrum of modalities that include monoclonal antibodies aimed at blocking or agonizing signaling, biologics such as recombinant proteins and peptides designed to modulate interaction surfaces, and gene therapy vectors engineered for cell-specific modulation. The interplay between scientific understanding and modality capabilities determines candidate profiles and clinical hypotheses. As stakeholders prioritize indications, they balance immunosuppressive needs in autoimmune disease and transplant rejection against immune activation strategies in oncology. These considerations establish the foundation for subsequent sections that explore landscape shifts, tariff implications, segmentation intelligence, regional dynamics, competitive movement, and practical recommendations for organizations engaged with this target.

How scientific breakthroughs, modality innovations, and translational strategy evolution are fundamentally reframing CD40 ligand therapeutic development and partnership models

The CD40 ligand landscape has undergone transformative shifts as scientific revelations, platform maturation, and regulatory precedents converge to reshape development priorities. First, a deeper mechanistic resolution of CD40L interactions with antigen-presenting cells and B cells has refined target engagement strategies; sponsors are increasingly optimizing paratope design and Fc engineering to decouple beneficial immunomodulation from thromboinflammatory liabilities. Concurrently, the rise of next-generation modalities-ranging from engineered monoclonal antibodies with modified effector functions to peptide antagonists and recombinant biologics-has expanded the toolbox available to scientists and clinicians.

In parallel, translational pathways have shifted. Oncology programs are layering CD40/CD40L targeting into rational combination regimens with checkpoint inhibitors and cellular therapies, driven by preclinical synergy and early clinical signals. On the autoimmune front, precision medicine approaches leveraging biomarker-driven patient selection are helping to de-risk trials and shorten time-to-signal. Supply chain and manufacturing advances, including stabilized formulations amenable to lyophilization and improved viral vector production processes, are reducing technical hurdles for modality diversification. Together, these trends are catalyzing a more modular, risk-calibrated development environment where scientific nuance, platform choice, and clinical strategy interact to determine program viability.

Assessment of how evolving U.S. tariff dynamics in 2025 subtly reshape supply chains, manufacturing decisions, and clinical development planning for CD40 ligand initiatives

U.S. tariff policy developments and broader trade dynamics as of 2025 present nuanced implications for the CD40 ligand ecosystem, affecting supply chains, reagent costs, and cross-border collaboration. Tariff-induced increases in the cost of imported raw materials, single-use systems, and certain biologics inputs can pressure manufacturing economics for both clinical and commercial-scale production. These cost dynamics tend to disproportionately impact smaller biotech firms and academic spinouts that operate on constrained budgets and have limited bargaining power with suppliers.

In response, organizations are adapting through sourcing diversification, nearshoring of critical manufacturing steps, and renegotiation of supplier contracts to mitigate exposure. The potential for delayed instrument shipments and reagents requires more conservative clinical supply lead times and contingency planning, which in turn influences trial timelines and regulatory interactions. On the positive side, policy-driven incentives for domestic biomanufacturing and strategic stockpiling of key materials can catalyze investment in resilient capacity. For cross-border collaborations, contractual frameworks increasingly incorporate explicit tariff pass-through clauses and scenario-based budgets, fostering clearer risk allocation between partners and reducing downstream disputes.

Actionable segmentation insights that map indication-specific clinical requirements, modality implications, end-user capabilities, and formulation considerations for strategic prioritization

A rigorous segmentation lens clarifies where scientific opportunity and commercial potential intersect across indications, product types, end users, and formulation choices. By indication, clinical and translational efforts span autoimmune disease-including lupus, multiple sclerosis, and rheumatoid arthritis-alongside infectious disease, oncology broken down into hematologic malignancies (leukemia and lymphoma) and solid tumors (melanoma and non small cell lung cancer), and transplant rejection. Each indication category brings distinct target validation requirements, safety tolerances, and regulatory expectations that influence trial design and go/no-go criteria.

From a product type perspective, development pathways vary markedly between gene therapy vectors, monoclonal antibodies, peptides, and recombinant proteins; vector-based approaches demand specialized manufacturing and long-term safety surveillance, while monoclonal antibodies rely on established biologics pathways and scalable production platforms. End users encompass biotech companies, contract research organizations, pharmaceutical manufacturers, and research institutions, with the latter including academic institutions and clinical laboratories that drive early discovery and biomarker validation. Finally, formulation choices between liquid and lyophilized powder formats affect stability, cold-chain logistics, and patient access strategies. When these segmentation dimensions are integrated, they reveal differentiated routes to clinical proof, partnership value creation, and commercialization readiness.

Regional dynamics and strategic implications across the Americas, Europe, Middle East & Africa, and Asia-Pacific that influence development pacing, manufacturing, and access strategies

Regional dynamics play a deterministic role in shaping clinical development pathways, regulatory strategy, and commercialization approaches for CD40 ligand programs. In the Americas, advanced clinical trial infrastructure, established biomanufacturing capacity, and active investor communities foster rapid proof-of-concept development and enable earlier access to pivotal studies. Regulatory engagement in this region tends to emphasize robust safety datasets and well-defined benefit-risk justifications, which informs global development planning and labeling strategies.

In Europe, the Middle East & Africa, regulatory harmonization efforts and mature clinical networks support multi-center trials, while region-specific reimbursement frameworks and payer expectations require early health economic planning. Academic centers in this region also remain critical sources of translational science and investigator-initiated studies. The Asia-Pacific landscape combines rapid patient recruitment capacity and growing manufacturing competence with diverse regulatory pathways; this diversity necessitates tailored regional strategies that account for differing acceptance of novel modalities and varying infrastructure maturity. Across regions, stakeholders are increasingly pursuing geographically stratified development plans and manufacturing footprints to optimize timelines, cost, and market access outcomes.

Competitive and collaborative dynamics across established pharma, biotech innovators, academic spinouts, and service partners that are shaping CD40 ligand program trajectories

The competitive environment around CD40 ligand programs is characterized by a mix of established pharmaceutical companies, innovative biotechnology firms, academic spinouts, and specialized contract research and manufacturing organizations supporting translational progress. Established organizations contribute platform-scale manufacturing expertise and regulatory experience that are essential for late-stage development, while smaller biotechnology firms and academic teams are often the source of early-stage innovation, novel mechanism-of-action insights, and nimble clinical proof-of-concept studies.

Partnership models range from research collaborations and licensing arrangements to co-development and supply agreements, reflecting the complementary capabilities required across discovery, translational validation, and commercialization. Contract research organizations and contract manufacturing partners have become strategic extensions of sponsor teams, enabling rapid scale-up and specialized assay development. Across the landscape, success increasingly depends on the ability to combine deep mechanistic science with operational excellence in manufacturing, regulatory strategy, and payer engagement to convert early signals into durable therapeutic franchises.

Practical, multi-layered recommendations for program prioritization, partnership design, supply chain resilience, and regulator-payer engagement to accelerate CD40 ligand success

Industry leaders should adopt a multi-dimensional strategy that balances scientific rigor with operational resilience to maximize the likelihood of clinical and commercial success in CD40 ligand endeavors. First, prioritize robust target and safety de-risking through rigorous preclinical models and early biomarker programs that directly inform patient selection and endpoint design. Investing in translational medicine capabilities will improve signal detection and increase the probability of decisive outcomes in early trials.

Second, structure partnerships to align incentives and share downstream risk; co-development agreements with clear governance and milestone frameworks will accelerate capability access while minimizing executional friction. Third, reinforce supply chain resilience by diversifying suppliers, considering regional manufacturing options, and incorporating tariff and logistics contingencies into contracting. Fourth, optimize modality choice relative to the indication: for autoimmune and transplant applications favor modalities with well-characterized safety profiles, while in oncology evaluate combinations and engineered modalities that amplify immune activation with controllable toxicity. Finally, proactively engage regulators and payers with early health economic modeling and real-world evidence plans to streamline development pathways and facilitate reimbursement conversations.

Transparent multipronged research approach integrating expert interviews, literature synthesis, and multi-source triangulation to ensure robust CD40 ligand insights and replicable conclusions

The research methodology underpinning this analysis combined a structured synthesis of peer-reviewed literature, regulatory guidances, clinical trial registries, and validated primary intelligence to ensure balanced, evidence-based conclusions. Primary inputs included in-depth interviews with translational scientists, clinical investigators, manufacturing experts, and commercial leaders who provided perspective on modality selection, trial design, manufacturing constraints, and regional execution challenges. These qualitative insights were triangulated with secondary sources, including scientific publications, conference disclosures, and public regulatory filings, to corroborate thematic findings and detect emerging signals.

Analytic rigor was maintained through cross-validation of claims across multiple data streams, careful documentation of assumptions, and sensitivity checks for geopolitical and supply chain risks. Segmentation frameworks were constructed to reflect actionable decision gates across indication, product type, end user, and formulation. Throughout the research process, emphasis was placed on transparency of method and replicability of key analyses to ensure that stakeholders can adapt findings to their proprietary contexts and evolving evidence bases.

Conclusive synthesis highlighting the balance between scientific promise and executional challenges in converting CD40 ligand discoveries into viable therapeutic interventions

The cumulative picture for CD40 ligand research and development is one of cautious optimism tempered by technical and operational complexity. Scientific advances have clarified therapeutic windows and uncovered opportunities to harness or restrain immune activity across a range of indications. At the same time, modality-specific manufacturing demands, safety considerations, and evolving trade dynamics require pragmatic, well-resourced development strategies. The balance between innovation and execution will determine which programs progress from proof-of-concept to sustainable clinical utility.

For decision-makers, the imperative is to align scientific hypothesis testing with operational preparedness: design trials that are biologically informed, secure manufacturing pathways that reduce timing risk, and craft commercial plans that anticipate regional regulatory and payer nuances. Organizations that integrate translational depth with strategic partnerships and resilient supply networks will be best positioned to translate CD40 ligand science into patient-impacting therapies. The path forward is navigable but requires disciplined prioritization, cross-functional coordination, and proactive risk mitigation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. CD40 Ligand Market, by Product Type

  • 8.1. Gene Therapy Vector
  • 8.2. Monoclonal Antibody
  • 8.3. Peptide
  • 8.4. Recombinant Protein

9. CD40 Ligand Market, by Form

  • 9.1. Liquid
  • 9.2. Lyophilized Powder

10. CD40 Ligand Market, by Indication

  • 10.1. Autoimmune Disease
    • 10.1.1. Lupus
    • 10.1.2. Multiple Sclerosis
    • 10.1.3. Rheumatoid Arthritis
  • 10.2. Infectious Disease
  • 10.3. Oncology
    • 10.3.1. Hematologic Malignancies
      • 10.3.1.1. Leukemia
      • 10.3.1.2. Lymphoma
    • 10.3.2. Solid Tumors
      • 10.3.2.1. Melanoma
      • 10.3.2.2. Non Small Cell Lung Cancer
  • 10.4. Transplant Rejection

11. CD40 Ligand Market, by End User

  • 11.1. Biotech Companies
  • 11.2. Contract Research Organizations
  • 11.3. Pharmaceutical Manufacturers
  • 11.4. Research Institutions
    • 11.4.1. Academic Institutions
    • 11.4.2. Clinical Laboratories

12. CD40 Ligand Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. CD40 Ligand Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. CD40 Ligand Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States CD40 Ligand Market

16. China CD40 Ligand Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc.
  • 17.6. Amgen Inc.
  • 17.7. AstraZeneca PLC
  • 17.8. Bayer AG
  • 17.9. Biogen Inc.
  • 17.10. Bristol-Myers Squibb Company
  • 17.11. Eli Lilly and Company
  • 17.12. F. Hoffmann-La Roche Ltd
  • 17.13. Gilead Sciences, Inc.
  • 17.14. GlaxoSmithKline plc
  • 17.15. Johnson & Johnson Services, Inc.
  • 17.16. Merck & Co., Inc.
  • 17.17. Novartis AG
  • 17.18. Novo Nordisk A/S
  • 17.19. Pfizer Inc.
  • 17.20. Regeneron Pharmaceuticals, Inc.
  • 17.21. Sanofi
  • 17.22. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL CD40 LIGAND MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CD40 LIGAND MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CD40 LIGAND MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CD40 LIGAND MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CD40 LIGAND MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CD40 LIGAND MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CD40 LIGAND MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CD40 LIGAND MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CD40 LIGAND MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CD40 LIGAND MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES CD40 LIGAND MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA CD40 LIGAND MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CD40 LIGAND MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CD40 LIGAND MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CD40 LIGAND MARKET SIZE, BY GENE THERAPY VECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CD40 LIGAND MARKET SIZE, BY GENE THERAPY VECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CD40 LIGAND MARKET SIZE, BY GENE THERAPY VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CD40 LIGAND MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CD40 LIGAND MARKET SIZE, BY MONOCLONAL ANTIBODY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CD40 LIGAND MARKET SIZE, BY MONOCLONAL ANTIBODY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CD40 LIGAND MARKET SIZE, BY PEPTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CD40 LIGAND MARKET SIZE, BY PEPTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CD40 LIGAND MARKET SIZE, BY PEPTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CD40 LIGAND MARKET SIZE, BY RECOMBINANT PROTEIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CD40 LIGAND MARKET SIZE, BY RECOMBINANT PROTEIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CD40 LIGAND MARKET SIZE, BY RECOMBINANT PROTEIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CD40 LIGAND MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CD40 LIGAND MARKET SIZE, BY LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CD40 LIGAND MARKET SIZE, BY LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CD40 LIGAND MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CD40 LIGAND MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CD40 LIGAND MARKET SIZE, BY LYOPHILIZED POWDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CD40 LIGAND MARKET SIZE, BY LYOPHILIZED POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CD40 LIGAND MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CD40 LIGAND MARKET SIZE, BY AUTOIMMUNE DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CD40 LIGAND MARKET SIZE, BY AUTOIMMUNE DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CD40 LIGAND MARKET SIZE, BY AUTOIMMUNE DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CD40 LIGAND MARKET SIZE, BY AUTOIMMUNE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CD40 LIGAND MARKET SIZE, BY LUPUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CD40 LIGAND MARKET SIZE, BY LUPUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CD40 LIGAND MARKET SIZE, BY LUPUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CD40 LIGAND MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CD40 LIGAND MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CD40 LIGAND MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CD40 LIGAND MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CD40 LIGAND MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CD40 LIGAND MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CD40 LIGAND MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CD40 LIGAND MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CD40 LIGAND MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CD40 LIGAND MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CD40 LIGAND MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CD40 LIGAND MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CD40 LIGAND MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CD40 LIGAND MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CD40 LIGAND MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CD40 LIGAND MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CD40 LIGAND MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CD40 LIGAND MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CD40 LIGAND MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CD40 LIGAND MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CD40 LIGAND MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CD40 LIGAND MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CD40 LIGAND MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CD40 LIGAND MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CD40 LIGAND MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CD40 LIGAND MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CD40 LIGAND MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CD40 LIGAND MARKET SIZE, BY MELANOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CD40 LIGAND MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CD40 LIGAND MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CD40 LIGAND MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CD40 LIGAND MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CD40 LIGAND MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CD40 LIGAND MARKET SIZE, BY TRANSPLANT REJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CD40 LIGAND MARKET SIZE, BY TRANSPLANT REJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CD40 LIGAND MARKET SIZE, BY TRANSPLANT REJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CD40 LIGAND MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CD40 LIGAND MARKET SIZE, BY BIOTECH COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CD40 LIGAND MARKET SIZE, BY BIOTECH COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CD40 LIGAND MARKET SIZE, BY BIOTECH COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CD40 LIGAND MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CD40 LIGAND MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CD40 LIGAND MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CD40 LIGAND MARKET SIZE, BY PHARMACEUTICAL MANUFACTURERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CD40 LIGAND MARKET SIZE, BY PHARMACEUTICAL MANUFACTURERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CD40 LIGAND MARKET SIZE, BY PHARMACEUTICAL MANUFACTURERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CD40 LIGAND MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CD40 LIGAND MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CD40 LIGAND MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CD40 LIGAND MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CD40 LIGAND MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CD40 LIGAND MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CD40 LIGAND MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CD40 LIGAND MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CD40 LIGAND MARKET SIZE, BY CLINICAL LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CD40 LIGAND MARKET SIZE, BY CLINICAL LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CD40 LIGAND MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS CD40 LIGAND MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS CD40 LIGAND MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS CD40 LIGAND MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS CD40 LIGAND MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS CD40 LIGAND MARKET SIZE, BY AUTOIMMUNE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS CD40 LIGAND MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS CD40 LIGAND MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS CD40 LIGAND MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS CD40 LIGAND MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS CD40 LIGAND MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA CD40 LIGAND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA CD40 LIGAND MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA CD40 LIGAND MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA CD40 LIGAND MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA CD40 LIGAND MARKET SIZE, BY AUTOIMMUNE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA CD40 LIGAND MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA CD40 LIGAND MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA CD40 LIGAND MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA CD40 LIGAND MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA CD40 LIGAND MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA CD40 LIGAND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA CD40 LIGAND MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA CD40 LIGAND MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA CD40 LIGAND MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA CD40 LIGAND MARKET SIZE, BY AUTOIMMUNE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA CD40 LIGAND MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA CD40 LIGAND MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA CD40 LIGAND MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA CD40 LIGAND MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA CD40 LIGAND MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA CD40 LIGAND MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA CD40 LIGAND MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA CD40 LIGAND MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA CD40 LIGAND MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA CD40 LIGAND MARKET SIZE, BY AUTOIMMUNE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA CD40 LIGAND MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA CD40 LIGAND MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA CD40 LIGAND MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA CD40 LIGAND MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA CD40 LIGAND MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE CD40 LIGAND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE CD40 LIGAND MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE CD40 LIGAND MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE CD40 LIGAND MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE CD40 LIGAND MARKET SIZE, BY AUTOIMMUNE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE CD40 LIGAND MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE CD40 LIGAND MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE CD40 LIGAND MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE CD40 LIGAND MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE CD40 LIGAND MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST CD40 LIGAND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST CD40 LIGAND MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST CD40 LIGAND MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST CD40 LIGAND MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST CD40 LIGAND MARKET SIZE, BY AUTOIMMUNE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST CD40 LIGAND MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST CD40 LIGAND MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST CD40 LIGAND MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST CD40 LIGAND MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST CD40 LIGAND MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA CD40 LIGAND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA CD40 LIGAND MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA CD40 LIGAND MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA CD40 LIGAND MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA CD40 LIGAND MARKET SIZE, BY AUTOIMMUNE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA CD40 LIGAND MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA CD40 LIGAND MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA CD40 LIGAND MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA CD40 LIGAND MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA CD40 LIGAND MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC CD40 LIGAND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC CD40 LIGAND MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC CD40 LIGAND MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC CD40 LIGAND MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC CD40 LIGAND MARKET SIZE, BY AUTOIMMUNE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC CD40 LIGAND MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC CD40 LIGAND MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC CD40 LIGAND MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC CD40 LIGAND MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC CD40 LIGAND MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL CD40 LIGAND MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN CD40 LIGAND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN CD40 LIGAND MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN CD40 LIGAND MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN CD40 LIGAND MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN CD40 LIGAND MARKET SIZE, BY AUTOIMMUNE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN CD40 LIGAND MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN CD40 LIGAND MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN CD40 LIGAND MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN CD40 LIGAND MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN CD40 LIGAND MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 178. GCC CD40 LIGAND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. GCC CD40 LIGAND MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. GCC CD40 LIGAND MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 181. GCC CD40 LIGAND MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 182. GCC CD40 LIGAND MARKET SIZE, BY AUTOIMMUNE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 183. GCC CD40 LIGAND MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 184. GCC CD40 LIGAND MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 185. GCC CD40 LIGAND MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 186. GCC CD40 LIGAND MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. GCC CD40 LIGAND MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION CD40 LIGAND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION CD40 LIGAND MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION CD40 LIGAND MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION CD40 LIGAND MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION CD40 LIGAND MARKET SIZE, BY AUTOIMMUNE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION CD40 LIGAND MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION CD40 LIGAND MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION CD40 LIGAND MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION CD40 LIGAND MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION CD40 LIGAND MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS CD40 LIGAND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS CD40 LIGAND MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS CD40 LIGAND MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS CD40 LIGAND MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS CD40 LIGAND MARKET SIZE, BY AUTOIMMUNE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS CD40 LIGAND MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS CD40 LIGAND MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS CD40 LIGAND MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS CD40 LIGAND MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS CD40 LIGAND MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 208. G7 CD40 LIGAND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. G7 CD40 LIGAND MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. G7 CD40 LIGAND MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 211. G7 CD40 LIGAND MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 212. G7 CD40 LIGAND MARKET SIZE, BY AUTOIMMUNE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 213. G7 CD40 LIGAND MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 214. G7 CD40 LIGAND MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 215. G7 CD40 LIGAND MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 216. G7 CD40 LIGAND MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. G7 CD40 LIGAND MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 218. NATO CD40 LIGAND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. NATO CD40 LIGAND MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. NATO CD40 LIGAND MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 221. NATO CD40 LIGAND MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 222. NATO CD40 LIGAND MARKET SIZE, BY AUTOIMMUNE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 223. NATO CD40 LIGAND MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 224. NATO CD40 LIGAND MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 225. NATO CD40 LIGAND MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 226. NATO CD40 LIGAND MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. NATO CD40 LIGAND MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL CD40 LIGAND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES CD40 LIGAND MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES CD40 LIGAND MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES CD40 LIGAND MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES CD40 LIGAND MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES CD40 LIGAND MARKET SIZE, BY AUTOIMMUNE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES CD40 LIGAND MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES CD40 LIGAND MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES CD40 LIGAND MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES CD40 LIGAND MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES CD40 LIGAND MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA CD40 LIGAND MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA CD40 LIGAND MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA CD40 LIGAND MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA CD40 LIGAND MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA CD40 LIGAND MARKET SIZE, BY AUTOIMMUNE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA CD40 LIGAND MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA CD40 LIGAND MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA CD40 LIGAND MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA CD40 LIGAND MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA CD40 LIGAND MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)